Developer docs
API playgroundTry for free, no card

Search company profiles

SAI Life Sciences

Full company profile

uuid0000631

Namestring
SAI Life Sciences
Legal namestring
Sai Life Sciences Limited
Websiteurl
sailife.com
Company typeenum
Public
Founded yearint
1999
Descriptiontext

SAI Life Sciences Limited is an India-headquartered Contract Research, Development, and Manufacturing Organization (CRDMO) founded in 1999 in Hyderabad and listed on BSE and NSE since December 2024. The company provides integrated drug discovery, development, and manufacturing services across small molecules and newer modalities (antibody-drug conjugates, peptides, oligonucleotides, and lipids) to global pharmaceutical and biotechnology innovators, serving 19 of the top 25 global pharma companies and a broader base of 300+ innovator pharma and biotech clients across the US, UK, EU, and Japan. The company's core products span Integrated Drug Discovery (medicinal chemistry, biology, DMPK, toxicology, in vivo pharmacology), Drug Substance Development (process development, analytical development, process engineering, particle science, developability), Drug Substance Manufacturing (clinical and commercial scale API manufacturing at Bidar), and Formulation Services (NCE formulation, clinical supplies), all delivered through co-located multidisciplinary teams that create an 'innovation corridor' for real-time collaboration.

SAI's technology stack is differentiated by proprietary platforms including High-Throughput Experimentation (HTE) for microscale screening with full traceability, commercial-scale photo flow chemistry at the Bidar API site, biocatalyst screening, particle science and solid-state characterization, and AI-driven retrosynthetic analysis integrated via partnership with Chemical.AI. The company employs over 3,400 scientists and professionals across India, the UK, and the US, with key sites in Hyderabad (integrated R&D campus), Bidar (API manufacturing), Manchester (process R&D), and Boston/Cambridge (discovery biology). Capacity expansion is underway with the new CMC Process R&D Center at Hyderabad (completion September 2026) doubling process R&D capacity and adding peptide and oligonucleotide capabilities, alongside a new Medicinal Chemistry block inaugurated in May 2026.

The business model is B2B professional services under quote-based contracts tailored to client program scope, following a 'follow-the-molecule' approach that captures revenue from discovery through commercial manufacturing. FY26 revenue was ₹2,241.62 crore (~$267M USD), growing 29% YoY, with EBITDA up 56% and PAT up 105%. Revenue mix has shifted toward large pharma clients (from 28% to 49% over four years), with management guiding 15-20% annual growth and steady-state EBITDA margins of 28-30%. The company is led by founder-MD & CEO Krishna Kanumuri (joined 2004) with senior leadership spanning former executives from Merck Research Labs, Novartis, Dana-Farber, GSK, and Agios.

Short descriptiontext

SAI Life Sciences is an India-headquartered CRDMO providing integrated drug discovery, development, and manufacturing services across small molecules and new modalities (ADCs, peptides, oligonucleotides) to 19 of the top 25 global pharma companies and 300+ biotech innovators across the US, UK, EU, and Japan.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research manufacturing, drug discovery services, API manufacturing, pharmaceutical development, CRDMO services
Industry4 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research, Development, and Manufacturing (CRDMO) Services
TypeProfessional Services
Description

Sai Life Sciences operates as a CRDMO providing integrated services across the drug development continuum. Revenue is generated through service contracts spanning discovery services (medicinal chemistry, biology, DMPK, toxicology), drug substance development, drug substance manufacturing (clinical and commercial scale API manufacturing), and formulations development. The company follows a 'follow-the-molecule' model where it partners with pharmaceutical innovators from discovery through commercial manufacturing, providing long-term revenue visibility. The company reported strong growth with FY26 revenue of ₹2,241.62 crore (29% YoY growth), EBITDA up 56% and PAT up 105-109%.

economictimes.indiatimes.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Sai Life Sciences operates as a Contract Research, Development, and Manufacturing Organization (CRDMO), providing integrated drug discovery, drug substance development, drug substance manufacturing, and formulation services across small molecules and new modalities (antibody-drug conjugates, peptides, oligonucleotides, lipids). The company partners with pharmaceutical and biotechnology innovators on a "follow-the-molecule" basis, advancing programs from target validation and medicinal chemistry through process development, scale-up, clinical supplies, and commercial API manufacturing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Revenue from large pharma clients nearly doubled from 28% to 49% over four years
+3 more records
Product overview1 text field

Sai Life Sciences is a Contract Research, Development, and Manufacturing Organization (CRDMO) offering an integrated platform spanning drug discovery through commercial manufacturing. The core offering comprises Discovery Services (Integrated Drug Discovery/IDD, CADD & Structural Biology, DMPK, In Vitro/In Vivo Biology, Safety & Toxicology, Synthetic & Medicinal Chemistry), Drug Substance Development (Process Development, Analytical Development, Process Engineering, Particle Science, Developability), Drug Substance Manufacturing, and Formulation Services. The company has expanded into New Modalities including Antibody-Drug Conjugates, Peptides, Oligonucleotides, and Lipids. Advanced technology platforms include High-Throughput Experimentation, Flow Chemistry, Photochemistry, and AI-driven retrosynthesis. Recent capacity additions include the new CMC Process R&D Center in Hyderabad and commercial-scale manufacturing capabilities in Bidar.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2026-05-08
Description

Collaboration to integrate AI-driven computer-aided synthesis design into Discovery Chemistry operations. AI-driven retrosynthetic analysis applied to ML-generated compounds, accelerating route design and improving synthetic efficiency.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-28
Description

Strategic collaboration establishing Sai's Boston laboratory as US execution and demonstration hub for Mabtech's EYRA multiplex immunology platform. Enables joint delivery of high-sensitivity multiplex cytokine and phenotyping workflows for biopharma and biotech clients in immuno-oncology, vaccines, inflammation, and cellular therapy. Includes co-branded demonstrations, pilot programs, shared thought leadership and case study development.

Strategic tierMinorTypeOthersAnnounced on2025-11-08
Description

CSR partnership for Child Sexual Abuse Prevention Program across ten government schools in Gachibowli, Hyderabad. Reached 3,400 children, trained over 100 teachers, and engaged community groups.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-08
Description

Integrated CMC Partnership announced to accelerate drug development for innovators. The partnership combines process development, manufacturing, and regulatory expertise across the three organizations to provide seamless end-to-end CMC services.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Syngene International
TypeDirect peer
Description

India-headquartered CRDMO offering integrated drug discovery, development, and manufacturing services to global pharma and biotech. Syngene is the closest comparable to SAI given overlapping integrated discovery-to-manufacturing scope, large-pharma customer base, and India cost-arbitrage positioning.

TypeDirect peer
Description

India-based CDMO offering drug substance and drug product development and manufacturing across small molecules and biologics. Directly comparable to SAI in API manufacturing, ADC capabilities, and integrated development services for global pharma clients.

TypeDirect peer
Description

Indian API and CDMO company providing contract development and manufacturing services for small molecules. Comparable to SAI's API manufacturing, process development, and emerging new-modality exposure, with a similar India-cost-arbitrage customer value proposition.

TypeDirect peer
Description

India-based API manufacturer and custom synthesis provider serving global pharma, with strong capabilities in complex small molecules and peptides. Comparable to SAI in API manufacturing scale, India footprint, and global pharma customer base.

TypeBroad incumbent
Description

Largest global CRDMO offering end-to-end discovery, development, and manufacturing services across small molecules, biologics, and new modalities. Comparable to SAI in integrated service scope but operates at materially larger scale and broader geographic footprint; serves as the incumbent whose position SAI is positioned to capture share from under the China+1 narrative.

TypeBroad incumbent
Description

Global CDMO leader across small molecules, biologics, and cell and gene therapy with deep expertise in new modalities including ADCs, peptides, and oligonucleotides. Comparable to SAI in new-modality capabilities and large-pharma customer base, though at much larger scale and broader geographic reach.

TypeOthers
Description

Global CDMO offering drug substance, drug product, and biologics development and manufacturing services. Comparable to SAI in formulation, clinical supply, and commercial manufacturing services for large pharma, with significantly larger scale and broader modality coverage.

TypeBroad incumbent
Description

Global CRO/CDMO through PPD offering integrated clinical research, biologics manufacturing, and pharma services. Comparable to SAI in serving large-pharma customers across the development lifecycle, with much larger scale, full clinical CRO capabilities, and broader therapeutic area coverage.

9Jubilant Biosys (Jubilant Pharmova)
TypeDirect peer
Description

India-based drug discovery and development services arm of Jubilant Pharmova, offering medicinal chemistry, biology, DMPK, and integrated discovery services to global pharma. Comparable to SAI's discovery services portfolio and India cost-arbitrage positioning with overlapping customer base.

10Suzhou Synthgene (China)
TypeRegional player
Description

China-based CRDMO offering gene synthesis, protein production, and peptide synthesis services primarily serving Asia-Pacific and global biotech clients. Comparable to SAI in peptide and new-modality capabilities but primarily serves a different geographic customer base, positioning it as a regional alternative rather than direct competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SAI Life Sciences

SAI Life Sciences is an India-headquartered CRDMO providing integrated drug discovery, development, and manufacturing services across small molecules and new modalities (ADCs, peptides, oligonucleotides) to 19 of the top 25 global pharma companies and 300+ biotech innovators across the US, UK, EU, and Japan.

What SAI Life Sciences does

SAI Life Sciences Limited is an India-headquartered Contract Research, Development, and Manufacturing Organization (CRDMO) founded in 1999 in Hyderabad and listed on BSE and NSE since December 2024. The company provides integrated drug discovery, development, and manufacturing services across small molecules and newer modalities (antibody-drug conjugates, peptides, oligonucleotides, and lipids) to global pharmaceutical and biotechnology innovators, serving 19 of the top 25 global pharma companies and a broader base of 300+ innovator pharma and biotech clients across the US, UK, EU, and Japan. The company's core products span Integrated Drug Discovery (medicinal chemistry, biology, DMPK, toxicology, in vivo pharmacology), Drug Substance Development (process development, analytical development, process engineering, particle science, developability), Drug Substance Manufacturing (clinical and commercial scale API manufacturing at Bidar), and Formulation Services (NCE formulation, clinical supplies), all delivered through co-located multidisciplinary teams that create an 'innovation corridor' for real-time collaboration.

SAI's technology stack is differentiated by proprietary platforms including High-Throughput Experimentation (HTE) for microscale screening with full traceability, commercial-scale photo flow chemistry at the Bidar API site, biocatalyst screening, particle science and solid-state characterization, and AI-driven retrosynthetic analysis integrated via partnership with Chemical.AI. The company employs over 3,400 scientists and professionals across India, the UK, and the US, with key sites in Hyderabad (integrated R&D campus), Bidar (API manufacturing), Manchester (process R&D), and Boston/Cambridge (discovery biology). Capacity expansion is underway with the new CMC Process R&D Center at Hyderabad (completion September 2026) doubling process R&D capacity and adding peptide and oligonucleotide capabilities, alongside a new Medicinal Chemistry block inaugurated in May 2026.

The business model is B2B professional services under quote-based contracts tailored to client program scope, following a 'follow-the-molecule' approach that captures revenue from discovery through commercial manufacturing. FY26 revenue was ₹2,241.62 crore (~$267M USD), growing 29% YoY, with EBITDA up 56% and PAT up 105%. Revenue mix has shifted toward large pharma clients (from 28% to 49% over four years), with management guiding 15-20% annual growth and steady-state EBITDA margins of 28-30%. The company is led by founder-MD & CEO Krishna Kanumuri (joined 2004) with senior leadership spanning former executives from Merck Research Labs, Novartis, Dana-Farber, GSK, and Agios.

SAI Life Sciences firmographics

Firmographics
Name
SAI Life Sciences
Legal name
Sai Life Sciences Limited
Website
https://sailife.com
Company type
Public
Founded year
1999
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
SAI Life Sciences is an India-headquartered CRDMO providing integrated drug discovery, development, and manufacturing services across small molecules and new modalities (ADCs, peptides, oligonucleotides) to 19 of the top 25 global pharma companies and 300+ biotech innovators across the US, UK, EU, and Japan.
Ownership category
akta.pro rank

SAI Life Sciences industry classification

Industry
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Contract research manufacturing
  • Drug discovery services
  • API manufacturing
  • Pharmaceutical development
  • CRDMO services

Where SAI Life Sciences is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices4 records

Markets served

SAI Life Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Research, Development, and Manufacturing (CRDMO) Services: Sai Life Sciences operates as a CRDMO providing integrated services across the drug development continuum. Revenue is generated through service contracts spanning discovery services (medicinal chemistry, biology, DMPK, toxicology), drug substance development, drug substance manufacturing (clinical and commercial scale API manufacturing), and formulations development. The company follows a 'follow-the-molecule' model where it partners with pharmaceutical innovators from discovery through commercial manufacturing, providing long-term revenue visibility. The company reported strong growth with FY26 revenue of ₹2,241.62 crore (29% YoY growth), EBITDA up 56% and PAT up 105-109%.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

SAI Life Sciences product offering

Product offering

Core offering

Sai Life Sciences operates as a Contract Research, Development, and Manufacturing Organization (CRDMO), providing integrated drug discovery, drug substance development, drug substance manufacturing, and formulation services across small molecules and new modalities (antibody-drug conjugates, peptides, oligonucleotides, lipids). The company partners with pharmaceutical and biotechnology innovators on a "follow-the-molecule" basis, advancing programs from target validation and medicinal chemistry through process development, scale-up, clinical supplies, and commercial API manufacturing.

Product overview

Sai Life Sciences is a Contract Research, Development, and Manufacturing Organization (CRDMO) offering an integrated platform spanning drug discovery through commercial manufacturing. The core offering comprises Discovery Services (Integrated Drug Discovery/IDD, CADD & Structural Biology, DMPK, In Vitro/In Vivo Biology, Safety & Toxicology, Synthetic & Medicinal Chemistry), Drug Substance Development (Process Development, Analytical Development, Process Engineering, Particle Science, Developability), Drug Substance Manufacturing, and Formulation Services. The company has expanded into New Modalities including Antibody-Drug Conjugates, Peptides, Oligonucleotides, and Lipids. Advanced technology platforms include High-Throughput Experimentation, Flow Chemistry, Photochemistry, and AI-driven retrosynthesis. Recent capacity additions include the new CMC Process R&D Center in Hyderabad and commercial-scale manufacturing capabilities in Bidar.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Revenue from large pharma clients nearly doubled from 28% to 49% over four years
  • +3 more outcomes

Companies that use SAI Life Sciences

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

SAI Life Sciences technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

SAI Life Sciences partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered supporting, core and minor.

  • Chemical.AIsupportingTechnology or Integration · 8 May 2026Collaboration to integrate AI-driven computer-aided synthesis design into Discovery Chemistry operations. AI-driven retrosynthetic analysis applied to ML-generated compounds, accelerating route design and improving synthetic efficiency.
  • MabtechcoreTechnology or Integration · 28 January 2026Strategic collaboration establishing Sai's Boston laboratory as US execution and demonstration hub for Mabtech's EYRA multiplex immunology platform. Enables joint delivery of high-sensitivity multiplex cytokine and phenotyping workflows for biopharma and biotech clients in immuno-oncology, vaccines, inflammation, and cellular therapy. Includes co-branded demonstrations, pilot programs, shared thought leadership and case study development.
  • Sankalp NGOminorOthers · 8 November 2025CSR partnership for Child Sexual Abuse Prevention Program across ten government schools in Gachibowli, Hyderabad. Reached 3,400 children, trained over 100 teachers, and engaged community groups.
  • Agility Life Sciences and Centrix Pharma SolutionscoreStrategic or Co-development Partner · 8 October 2025Integrated CMC Partnership announced to accelerate drug development for innovators. The partnership combines process development, manufacturing, and regulatory expertise across the three organizations to provide seamless end-to-end CMC services.

Scale indicators14 records

Recent moves9 records

Expansion highlights6 records

SAI Life Sciences competitors and assessment

Company assessment

Direct peers

  • Syngene International: India-headquartered CRDMO offering integrated drug discovery, development, and manufacturing services to global pharma and biotech. Syngene is the closest comparable to SAI given overlapping integrated discovery-to-manufacturing scope, large-pharma customer base, and India cost-arbitrage positioning.
  • Piramal Pharma Solutions: India-based CDMO offering drug substance and drug product development and manufacturing across small molecules and biologics. Directly comparable to SAI in API manufacturing, ADC capabilities, and integrated development services for global pharma clients.
  • Laurus Labs: Indian API and CDMO company providing contract development and manufacturing services for small molecules. Comparable to SAI's API manufacturing, process development, and emerging new-modality exposure, with a similar India-cost-arbitrage customer value proposition.
  • Divi's Laboratories: India-based API manufacturer and custom synthesis provider serving global pharma, with strong capabilities in complex small molecules and peptides. Comparable to SAI in API manufacturing scale, India footprint, and global pharma customer base.
  • Jubilant Biosys (Jubilant Pharmova): India-based drug discovery and development services arm of Jubilant Pharmova, offering medicinal chemistry, biology, DMPK, and integrated discovery services to global pharma. Comparable to SAI's discovery services portfolio and India cost-arbitrage positioning with overlapping customer base.

Broad incumbents

  • WuXi AppTec: Largest global CRDMO offering end-to-end discovery, development, and manufacturing services across small molecules, biologics, and new modalities. Comparable to SAI in integrated service scope but operates at materially larger scale and broader geographic footprint; serves as the incumbent whose position SAI is positioned to capture share from under the China+1 narrative.
  • Lonza Group: Global CDMO leader across small molecules, biologics, and cell and gene therapy with deep expertise in new modalities including ADCs, peptides, and oligonucleotides. Comparable to SAI in new-modality capabilities and large-pharma customer base, though at much larger scale and broader geographic reach.
  • Thermo Fisher Scientific (CDMO/PPD): Global CRO/CDMO through PPD offering integrated clinical research, biologics manufacturing, and pharma services. Comparable to SAI in serving large-pharma customers across the development lifecycle, with much larger scale, full clinical CRO capabilities, and broader therapeutic area coverage.

Others

  • Catalent (Novo Holdings): Global CDMO offering drug substance, drug product, and biologics development and manufacturing services. Comparable to SAI in formulation, clinical supply, and commercial manufacturing services for large pharma, with significantly larger scale and broader modality coverage.

Regional players

  • Suzhou Synthgene (China): China-based CRDMO offering gene synthesis, protein production, and peptide synthesis services primarily serving Asia-Pacific and global biotech clients. Comparable to SAI in peptide and new-modality capabilities but primarily serves a different geographic customer base, positioning it as a regional alternative rather than direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks4 records

Key highlights7 records

Customer concentration

SAI Life Sciences social profiles

Digital presence

SAI Life Sciences compliance and trust

Trust signal

Compliance7 records

SAI Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SAI Life Sciences leadership team

Management profile

Number of profiles

SAI Life Sciences funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SAI Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SAI Life Sciences

What does SAI Life Sciences do?

Sai Life Sciences operates as a Contract Research, Development, and Manufacturing Organization (CRDMO), providing integrated drug discovery, drug substance development, drug substance manufacturing, and formulation services across small molecules and new modalities (antibody-drug conjugates, peptides, oligonucleotides, lipids). The company partners with pharmaceutical and biotechnology innovators on a "follow-the-molecule" basis, advancing programs from target validation and medicinal chemistry through process development, scale-up, clinical supplies, and commercial API manufacturing.

Is SAI Life Sciences a public or private company?

SAI Life Sciences is a public company. It is currently operating.

When was SAI Life Sciences founded?

SAI Life Sciences was founded in 1999. It employs 1,001 to 5,000 people.

Where is SAI Life Sciences based?

SAI Life Sciences is headquartered in Hyderabad, India, in the Asia region.

How does SAI Life Sciences make money?

One revenue line is on record: contract Research, Development, and Manufacturing (CRDMO) Services.

Who are SAI Life Sciences's main competitors?

Direct peers on record are Syngene International, Piramal Pharma Solutions, Laurus Labs, Divi's Laboratories and Jubilant Biosys (Jubilant Pharmova). Broad incumbents are WuXi AppTec, Lonza Group and Thermo Fisher Scientific (CDMO/PPD). Catalent (Novo Holdings) is listed as an others. Suzhou Synthgene (China) is listed as a regional player.

Does SAI Life Sciences have an API?

No public API is recorded for SAI Life Sciences.

What industry is SAI Life Sciences in?

Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CNBCTV18Sai Life reiterates 15-20% long-term growth targets as global pharma firms diversify beyond China - CNBC TV18Sai Life Sciences CFO Siva Chittor reiterated long-term targets of 15-20% annual revenue growth and 28-30% EBITDA margins. The company is expanding into peptides and clinical formulations, citing global pharma firms' urgency to diversify supply chains beyond China. It expects continued growth opportunities for Indian CRDMO players.Zee BusinessPharma Stocks Rally! Nifty Pharma hits 52-week high, gains 27% in 2026, outperforms Nifty 50 – What's driving rally?Pharmaceutical stocks rallied on November 9, with the Nifty Pharma index hitting a fresh 52-week high after Q2 FY27 earnings. The index gained 1.39% to 28,822.80, while top gainers included Gland Pharma and Sai Life Sciences. The index has outperformed the Nifty 50 over multiple periods.Business StandardPharma shares shine: Sai, Gland, Divi's, Laurus, Glenmark surge up to 9%Pharma stocks including Divi's, Laurus, Sai, Gland, and Glenmark rose 5-9% on the NSE after strong Q2 earnings. The Nifty Pharma index hit a new high of 29,224.85, up 3%, while analysts set price targets for Divi's and Sai Life Sciences.Business StandardMultibagger stock today: Sai Life Sciences surges 9% to record high after Q2 nosSai Life Sciences shares surged nearly 9% to an all-time high of ₹1,897.30 on Monday after Q2FY27 results. Net profit rose 17% to ₹98 crore and revenue grew 23% to ₹659 crore, while Ebitda margin fell to 28%. The company expects its integrated collaboration to be fully functional in Q3.Business TodayDivis Laboratories, Gland Pharma, Sai Life Sciences shares hit 52 week highs; here's why - BusinessTodayShares of Divis Laboratories, Gland Pharma, and Sai Life Sciences hit 52-week highs on Monday after Divis Labs reported Q2 earnings. Divis Labs' net profit rose 64% to Rs 1,127 crore, while Gland Pharma's profit increased 58.2% to Rs 291 crore. The rally was driven by strong quarterly results across the three firms.The Times of IndiaSai Life Sciences shares jump 9%, multibagger stock rallies 19% in 3 days after Q2 results. Why Jefferies hiked target priceSai Life Sciences shares rose 12% on Friday after Q2 results, hitting a 52-week high of Rs 1,897.30. Net profit climbed 17% to Rs 98 crore, revenue up 23% to Rs 659 crore, and Jefferies raised its target to Rs 2,050, implying 18% upside.Simply Wall StSai Life Sciences Limited Just Beat Revenue By 11%: Here's What Analysts Think Will Happen NextSai Life Sciences reported Q4 revenue of ₹6.6b, beating expectations, with statutory EPS of ₹16.43 in line with forecasts. Analysts reconfirmed a 2027 revenue forecast of ₹26.2b, implying 11% growth, and a price target of ₹1,579. The company is expected to grow faster than the industry average.Business StandardPharma stocks rally: Aurobindo, Divi's, Glenmark, Symbiotec hit new highsNifty Pharma index rose 1% to a new high of 27,197.25 on Friday, with Aurobindo, Divi's, Glenmark, Symbiotec, and Sail Life Sciences hitting new highs. Symbiotec's shares jumped 20% on Q2 revenue growth of 43% to ₹280 crore, while Alembic's US sales surpassed $100 million quarterly.Business StandardSai Life soars 10%, hits record high on strong Q2 earningsSai Life Sciences shares surged 10.3% to a record ₹1,775 on the NSE after reporting Q2FY27 revenue of ₹659 crore, up 23% YoY, and PAT of ₹98 crore, up 17%. Management expects a stronger second half, with PL Capital initiating coverage and a target of ₹1,620.CNBCTV18Nifty 500: Sai Life Sciences hits record high; Astral shares hit 52-wk low on Q2 result - CNBC TV18Sai Life Sciences shares rose 9% to an all-time high of ₹1,750, while Astral shares fell over 12% to a fresh 52-week low after Q2 results. Thermax also slipped, with net profit down 4.2% to ₹115 crore. The sell-off weighed on the Nifty 500.